MSL
CNMD icon

Mackay Shields LLC’s CONMED CNMD Stock Holding History

Mackay Shields LLC’s Portfolio CNMD Stock Details CNMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15,700
Closed -$2.05M – 829
2021
Q1 		$2.05M Sell
15,700
-16,800
-52% -$2.02M 0.02% 759
2020
Q4 		$3.64M Sell
32,500
-5,400
-14% -$511K 0.03% 591
2020
Q3 		$2.98M Sell
37,900
-8,700
-19% -$710K 0.02% 615
2020
Q2 		$3.35M Buy
46,600
+12,500
+37% +$870K 0.03% 528
2020
Q1 		$1.95M Sell
34,100
-6,700
-16% -$618K 0.02% 678
2019
Q4 		$4.56M Sell
40,800
-6,000
-13% -$639K 0.03% 491
2019
Q3 		$4.5M Sell
46,800
-7,500
-14% -$704K 0.03% 536
2019
Q2 		$4.65M Buy
+54,300
New +$4.46M 0.03% 549
2019
Q1 		– Sell
-22,561
Closed -$1.45M – 1388
2018
Q4 		$1.45M Buy
22,561
+14,261
+172% +$976K 0.01% 788
2018
Q3 		$658K Buy
+8,300
New +$642K 0.01% 962

Other funds holding CNMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Mackay Shields LLC's CNMD Position: Q2 2021 in Review

Mackay Shields LLC sold out of CONMED (CNMD) in Q2 2021, closing a stake of 15,700 shares — an estimated $2.05M sold.

Mackay Shields LLC first reported a position in CNMD in Q3 2018 and held it in 10 quarters. The position peaked at $4.65M in Q2 2019. 252 funds tracked by Wall St. Rank hold CNMD as of Q2 2021.

  • Mackay Shields LLC reported no remaining CONMED position as of Q2 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 15,700 CONMED shares in Q2 2021, an estimated $2.05M.
  • Mackay Shields LLC first reported a position in CONMED in Q3 2018 and held it in 10 quarters.
  • Mackay Shields LLC's CONMED position peaked at $4.65M in Q2 2019.
  • 252 funds tracked by Wall St. Rank held CONMED as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.